       Document 0511
 DOCN  M9620511
 TI    Human studies in the development of human immunodeficiency virus
       vaccines.
 DT    9602
 AU    Dolin R; University of Rochester School of Medicine and Dentistry, New;
       York, USA.
 SO    J Infect Dis. 1995 Nov;172(5):1175-83. Unique Identifier : AIDSLINE
       MED/96036371
 AB    The safety and immunogenicity of candidate human immunodeficiency virus
       type 1 (HIV-1) vaccines have been studied in > 1500 healthy,
       seronegative (HIV-1-uninfected) subjects. HIV-1 envelope proteins, gp160
       and gp120, have been the most extensively investigated. A live virus
       vector construct, vaccinia with insertion of the HIV-1 env gene, has
       also been studied. HIV-1 candidate vaccines have been well tolerated,
       with no acute or longer-term serious toxicity. Intramuscular multidose
       gp120 vaccines induce neutralizing antibodies, lymphoproliferative
       responses, and anti-HIV-1 CD4 cytotoxic T cell (CTL) activity.
       Immunization with the vaccinia-env construct, followed by a boost with
       an envelope protein, also induces neutralizing antibodies, and
       anti-HIV-1 CTL activity (CD8, major histocompatibility complex class
       I-restricted) has been observed. To date, serum from vaccinees can
       neutralize laboratory-adapted HIV-1 strains in vitro but not primary
       isolates; the significance of this observation is unknown. Additional
       approaches to vaccination against HIV-1 are in development.
 DE    Acquired Immunodeficiency Syndrome/*IMMUNOLOGY  Animal  AIDS
       Vaccines/*IMMUNOLOGY/TOXICITY  Chimpansee troglodytes  Comparative Study
       Enzyme-Linked Immunosorbent Assay  Gene Products, env/IMMUNOLOGY
       Genetic Vectors  Human  HIV Antibodies/BIOSYNTHESIS/BLOOD  HIV Envelope
       Protein gp120/IMMUNOLOGY  HIV Seronegativity/*IMMUNOLOGY
       HIV-1/*IMMUNOLOGY  Neutralization Tests  Protein Precursors/IMMUNOLOGY
       Safety  Support, U.S. Gov't, P.H.S.  Vaccinia Virus  Viral Envelope
       Proteins/*IMMUNOLOGY  JOURNAL ARTICLE  REVIEW  REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

